Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Biden Administration Proposes Biosimilar Substitution Without Interchangeability

Mar 11, 2024

The Biden Administration proposes to amend s352 of the Public Health Service Act so that all approved biosimilars are deemed to be interchangeable with their respective reference drug.

On 11 March 2024, the Biden Administration released its 2025 Budget Proposal in which it recommends allowing biosimilar substitution without FDA’s determination of interchangeability.  According to U.S. Department of Health & Human Services (HHS):

The statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding, including among patients and healthcare providers, about the safety and effectiveness of biosimilars and about whether interchangeable biosimilars are safer or more effective than other biosimilars